Company / PP&E (Net)
TG Therapeutics, Inc. PP&E (Net) History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$95.0K
FY2023
5-year range
$95.0K / $600.0K
FY2019-FY2023
Trend
-69.1%
vs FY2022
Sector context
#187 of 193
Health Care
What the data says
Among 193 Health Care companies, TG Therapeutics, Inc. is in the bottom 3% for pp&e (net). Declined from $600,000 to $95,000 over the past 2 years.
Based on SEC 10-K filings.
$95,000 in FY2023 with a 5-year CAGR of -17.7%.
Declined from $600,000 to $95,000 over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -41.8%
- 5-Year CAGR
- -17.7%
- 10-Year CAGR
- -
Sector benchmark
Bottom 3% in Health CareTop 97% of 193This company $95.0K Sector average $777.6M
▼
-100.0% below sector average
Key checks
Key Insights
- 5-year CAGR of -17.7%, indicating a declining trend.
- In FY2023, pp&e (net) decreased 69.1% year-over-year.
- Ranks #187 out of 193 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 1.05 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $95.0K | -69.1% |
| FY2022 | $307.0K | -48.8% |
| FY2021 | $600.0K | +24.7% |
| FY2020 | $481.0K | +70.6% |
| FY2019 | $282.0K | +12.4% |
| FY2018 | $251.0K | +1.2% |
| FY2017 | $248.0K | -24.4% |
| FY2016 | $328.1K | +596.4% |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026